Comparison of Dynamic Phase Enhancement of Hepatocellular Carcinoma Using Gadoxetate Disodium vs Gadobenate Dimeglumine

Journal of Computer Assisted Tomography
Temel TirkesFatih Akisik

Abstract

To determine the differences in enhancement of hepatocellular carcinoma during the first 5 minutes of postcontrast phases with gadoxetic acid (Gd-EOB-DTPA) vs gadobenate dimeglumine. Ninety-five cirrhotic patients with hepatocellular carcinoma were examined on a 1.5-T scanner: 74 patients with Gd-BOPTA and 21 patients with Gd-EOB-DTPA. Same magnetic resonance imaging parameters were used for both groups. Gadoxetate isodium was administered at a dose of 0.025 mmol/kg; and Gd-BOPTA, at a dose of 0.1 mmol/kg. Mean contrast-to-noise ratios (CNR) were similar in arterial (P = 0.3), portal venous (P = 0.1), and 5-minute delayed phases (P = 0.73). The CNRs of lesions in the Gd-EOB-DTPA group were lower in arterial phase, although this did not reach statistical significance. The CNRs of Gd-EOB-DTPA during the equilibrium phase was higher (P = 0.006). Gadoxetate isodium resulted in lower CNR during the arterial phase and higher CNR during the portal venous, equilibrium, and 5-minute delayed phases compared with gadobenate dimeglumine using the Food and Drug Administration-approved doses; however, overall, there was no statistical significance (P = 0.077).

References

Jun 23, 2010·AJR. American Journal of Roentgenology·Kristina I RingeElmar M Merkle
Feb 24, 2011·Investigative Radiology·Takashi KatsubeTakamichi Murakami

❮ Previous
Next ❯

Citations

Nov 18, 2015·Korean Journal of Radiology : Official Journal of the Korean Radiological Society·Jimi HuhWei Chou Chang
May 29, 2021·Korean Journal of Radiology : Official Journal of the Korean Radiological Society·Seo Yeon YounSung Eun Rha
Jul 11, 2021·Magnetic Resonance Imaging Clinics of North America·Silvia D ChangVictoria Chernyak

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.